ProCE Banner Activity

Shifting the Paradigm: Targeting Weight Loss as a Primary Therapeutic Target in Type 2 Diabetes

Clinical Thought

Here’s my take on why it’s important to address weight loss for reducing the risk of comorbidities in patients with type 2 diabetes and the role of GLP-RAs and SGLT2 inhibitors in amplifying a healthier lifestyle.

Released: September 14, 2022

Expiration: December 31, 2023

Share

Faculty

Jennifer Clements

Jennifer Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM

Clinical Professor/Director of Pharmacy Education
Department of Clinical Pharmacy and Outcomes Science
University of South Carolina School of Medicine Greenville
Greenville, South Carolina

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an educational grant from

Lilly

Partners

ADCES

ProCE Banner

Faculty Disclosure

Primary Author

Jennifer Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM

Clinical Professor/Director of Pharmacy Education
Department of Clinical Pharmacy and Outcomes Science
University of South Carolina School of Medicine Greenville
Greenville, South Carolina

Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM: consultant/advisor/speaker: Novo Nordisk, Sanofi.